Please upgrade your browser.
Anti-tumor effect of ribavirin in combination with interferon-alpha on renal cell carcinoma cell lines in vitro
Ribavirin is an anti-viral drug; however, recent data suggest that it may also be effective in cancer therapy.
The vascular endothelial growth factor (VEGF) pathway blockers and mammalian target of rapamycin (mTOR) inhibitors have dramatically improved the treatment options and outcome for patients with advanced renal cell carcinoma (RCC).
Focal Therapy and Imaging in Prostate and Kidney Cancer
Professor Dilts has some suggestions how to improve the situation.
Dr. Bavesh Balar is a board-certified hematologist and oncologist on staff at CentraState Medical Center in Freehold, N.J.
You can be a part of an important study being conducted by researchers at Northwestern University.
The application deadline is September 25, 2014. Recipients will be announced in April 2015.
Clues about genetic alterations that may contribute to a rare form of kidney cancer have been discovered...
Diabetes mellitus is independently associated with an increased risk of mortality among clear cell renal cell carcinoma patients
Conflicting data exist regarding the interaction of diabetes mellitus (DM) with outcomes for patients with renal cell carcinoma (RCC).
Cancer simply may be here to stay.
|Powered by NeonCRM|